Skip to main content
. 2014 Mar 4;5(6):1646–1656. doi: 10.18632/oncotarget.1802

Figure 6. Increased AR-V expression in LNCaP tumors that have developed acquired resistance to enzalutamide.

Figure 6

A-D. qRT-PCR analysis of the levels of AR-V transcripts. Fold changes are calculated from the difference in mean ∆CT between the enzalutamide-sensitive and enzalutamide-resistant groups (2∆∆CT). E. Western blot analysis of the levels of AR-FL and AR-V proteins.